Your browser doesn't support javascript.
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.
Cortellini, Alessio; Salazar, Ramon; Gennari, Alessandra; Aguilar-Company, Juan; Bower, Mark; Bertuzzi, Alexia; Brunet, Joan; Lambertini, Matteo; Maluquer, Clara; Pedrazzoli, Paolo; Lee, Alvin Jx; Carmona-García, MCarmen; Newsom-Davis, Thomas; Van Hemelrijck, Mieke; Plaja, Andrea; Zambelli, Alberto; Tondini, Carlo; Generali, Daniele; Bertulli, Rossella; Diamantis, Nikolaos; Mukherjee, Uma; Rizzo, Gianpiero; Yu, Tamara; Zoratto, Federica; Bruna, Riccardo; Sureda, Anna; Martinez-Vila, Clara; Cantini, Luca; Mazzoni, Francesca; Grosso, Federica; Parisi, Alessandro; Saponara, Maristella; Prat, Aleix; Pinato, David J.
  • Cortellini A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: alessiocortellini@gmail.com.
  • Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Barcelona, Spain.
  • Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
  • Aguilar-Company J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Lambertini M; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
  • Maluquer C; Fundació Althaia Manresa, Manresa, Spain.
  • Pedrazzoli P; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia Italy.
  • Lee AJ; Cancer Division, University College London Hospital, London, UK.
  • Carmona-García M; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain.
  • Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK.
  • Van Hemelrijck M; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
  • Plaja A; Medical Oncology Department, B-ARGO Group, IGTP, Catalan Institute of Oncology, Badalona, Spain.
  • Zambelli A; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Tondini C; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
  • Generali D; Multidisciplinary Breast Pathology and Translational Research Unit, ASST Cremona, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Italy.
  • Bertulli R; Medical Oncology 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Diamantis N; Medical Oncology, Barts Health NHS Trust, London, UK.
  • Mukherjee U; Medical Oncology, Barts Health NHS Trust, London, UK.
  • Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Yu T; Cancer Division, University College London Hospital, London, UK.
  • Zoratto F; Medical Oncology, St Maria Goretti Hospital, Latina, Italy.
  • Bruna R; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy.
  • Sureda A; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain.
  • Martinez-Vila C; Fundació Althaia Manresa, Manresa, Spain.
  • Cantini L; Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy; Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.
  • Mazzoni F; Medical Oncology, Careggi University Hospital, Florence, Italy.
  • Grosso F; Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
  • Parisi A; Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
  • Saponara M; Melanoma and Sarcoma Medical Treatment Unit, IEO - Istituto Europeo di Oncologia, Milan, Italy.
  • Prat A; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
  • Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Eur J Cancer ; 170: 10-16, 2022 07.
Article in English | MEDLINE | ID: covidwho-1906967
ABSTRACT

INTRODUCTION:

A significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of care and oncological outcome. The long-term prevalence and clinical impact of the post-COVID-19 syndrome in patients with cancer are largely unknown.

METHODS:

In this study, we describe the time course of COVID-19 sequelae in patients with non-advanced cancers enrolled in the OnCovid registry.

RESULTS:

Overall, 186 patients were included, with a median observation period of 9.9 months (95%CI8,8-11.3) post-COVID-19 resolution. After a median interval of 2.3 months post-COVID-19 (interquartile range 1.4-3.7), 31 patients (16.6%) reported ≥1 sequelae, including respiratory complications (14, 7.6%), fatigue (13, 7.1%), neuro-cognitive sequelae (7, 3.8%). The vast majority of the patients were not vaccinated prior to COVID-19. COVID-19-related sequelae persisted in 9.8% and 8% of patients 6 and 12 months after COVID-19 resolution. Persistence of sequelae at first oncological follow-up was associated with history of complicated COVID-19 (45.2% vs 24.8%, p = 0.0223), irrespective of oncological features at COVID-19 diagnosis.

CONCLUSION:

This study confirms for the first time that, in a largely unvaccinated population, post-COVID-19 syndrome can affect a significant proportion of patients with non-advanced cancer who recovered from the acute illness. COVID-19 sequelae may persist up to 12 months in some patients, highlighting the need for dedicated prevention and supportive strategies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Eur J Cancer Year: 2022 Document Type: Article